logo

For the Inventor, By the Inventor

Dallas, TX, United States of America

John Dorrance Minna

This inventor holds 13 USPTO granted patents and 8 published patent applications. Top assignees: The University of Texas System, The United States of America, as Represented by the Secretary, Department of Health and Human Services, University of Houston System. Active years: 2002-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Dorrance Minna. Retrieved from https://idiyas.com/inventor/john-dorrance-minna

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 

% Patents Active = 69.2

Average Co-Inventor Count = 4.1

ph-index = 3

Forward Citations = 186(Granted Patents)


Company Filing History:

goldMedal12 out of 5,640 
 
The University of Texas System
 patents
silverMedal5 out of 3,697 
 
The United States of America, as Represented by the Secretary, Department of Health and Human Services
 patents
bronzeMedal2 out of 619 
 
University of Houston System
 patents
where one patent can have more than one assignee

Years Active: 2002-2024

Loading Chart...
13 patents (USPTO):Explore Patents
1. 11865157 - Compositions and methods of targeting cancer stem cells (2024-01-09),
2. 11660325 - Compositions and methods of targeting cancer stem cells (2023-05-30),
3. 11497740 - Use of Jumonji C demethylase inhibitors for the treatment and prevention of chemotherapy resistance and radioresistance in cancer (2022-11-15),
4. 9944951 - Chromosome 3p21.3 genes are tumor suppressors (2018-04-17),
5. 8324181 - Modulation of gene expression by oligomers targeted to chromosomal DNA (2012-12-04),
6. 7977468 - Chromosome 3p21.3 genes are tumor suppressors (2011-07-12),
7. 7902441 - Chromosome 3p21.3 genes are tumor suppressors (2011-03-08),
8. 7858592 - Interfering RNAs against the promoter region of P53 (2010-12-28),
9. 7781413 - SEMA3B inhibits tumor growth and induces apoptosis in cancer cells (2010-08-24),
10. 7709456 - Modulation of gene expression by oligomers targeted to chromosomal DNA (2010-05-04),
11. 6979724 - Calcium channel proteins (2005-12-27),
12. 6472154 - Polymorphic repeats in human genes (2002-10-29),
13. 6441156 - Calcium channel compositions and methods of use thereof (2002-08-27),

Title: The Innovative Contributions of John Dorrance Minna

Introduction

John Dorrance Minna, located in Dallas, TX, is a prominent inventor known for his significant contributions to the field of cancer research. With a total of 13 patents to his name, Minna's work focuses on developing novel pharmaceutical compositions that aim to address critical health challenges.

Latest Patents

Among his most notable recent patents are his innovative compositions and methods of targeting cancer stem cells. These patents describe pharmaceutical compositions containing peptoids of specific formulas capable of reducing the proliferation of cancer stem cells in subjects. Additionally, Minna's work includes methods for the detection and treatment of cancerous cell masses using these peptoids. His groundbreaking research has the potential to pave the way for more effective cancer therapies.

Career Highlights

Minna has worked with prestigious institutions, notably the University of Texas System and The United States of America as represented by the Secretary of the Department of Health and Human Services. His career reflects a dedication to research and innovation, aiming to make substantial contributions to healthcare through scientific advancements.

Collaborations

Throughout his career, Minna has collaborated with distinguished colleagues, including Michael I. Lerman and David R. Corey. These collaborations reflect a shared commitment to advancing the field of cancer research and developing effective treatment methodologies.

Conclusion

John Dorrance Minna's contributions to the medical field through his innovative patents are remarkable. With a focus on targeting cancer stem cells, his work holds promise for improved cancer treatment options. As he continues his research, the impact of his inventions may transform therapeutic approaches and enhance patient care in oncology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…